Sentences with phrase «for epipen»

In California, there are 3 types of plans that are the best option for EpiPen coverage, given the out of pocket cost to purchase an EpiPen pack and the premium cost of the plan.

The exception is Anthem Blue Cross still offers a silver plan with no prescription deductible, and you'll immediately pay only the $ 40 copay for each EpiPen pack.

Coverage for the EpiPen under these carriers will be the most favorable, with lower copays and more available coverage.

Part of the reason why figuring out how much an EpiPen will cost are the multiple factors that go into insurance coverage for EpiPen.

March 30, 2017 UChicago Medicine research finds patients face rising costs for EpiPen allergy drug Commercially insured patients who use the life - saving epinephrine auto - injector known as «EpiPen» have experienced skyrocketing out - of - pocket costs since 2007, according to research published March 27 in JAMA Internal Medicine.

Pharma company Mylan will pay out nearly $ 500 million in settlement claims for shorting the federal government and states for EpiPen rebates.

The increased price for the EpiPen — hike by some 400 percent — has led to bipartisan outrage toward Mylan as a generic version may soon be offered and calls for federal and state investigations grow.

It should be good for an EpiPen 2 - pack, and you can use the card as many times as you want until the end of the year.

Mylan points out there are online coupons for EpiPen customers.

Mylan has raised the price for the EpiPen, an auto - injector device that delivers epinephrine to counteract deadly allergic reactions which must be replaced on a yearly basis, more than 400 % over the last decade, putting families who have high deductible health insurance in a bind.

Mylan signed on famous spokespeople for EpiPen, including actress Sarah Jessica Parker and celebrity chef Amanda Freitag.

That's compared with the $ 600 that Mylan's been charging for an EpiPen two - pack.

Mylan CEO Heather Bresch trekked to the House of Representatives on Wednesday to testify about her company's controversial price hike for the EpiPen.

Mylan had not directly referenced the tax assumptions for its EpiPen profit estimates, neither in its September 15, 2016, letter to the Committee, nor in the documents that the company produced.»

In a CNBC interview in August, Bresch blamed this complexity and the middlemen that are able to profit from it for EpiPen's price hikes.

The U.S. market is the most lucrative for EpiPen, where a two - pack of the generic injectors retails for $ 300.

Mylan drew major flak last year after news broke that it had steadily increased the list price for an EpiPen two - pack from about $ 100 to more than $ 600 in less than a decade.

The PR fiasco forced the company to buttress its own patient assistance and rebate programs for the EpiPen and to introduce an authorized generic version of the device at half the price.

«You failed to thoroughly investigate multiple serious component and product failures for your EpiPen products, including failures associated with patient deaths and severe illness,» the warning read.

Mylan's CEO, Heather Bresch, later had to testify before Congress, class - action lawsuits have been filed against the company, and Mylan in May was accused of overcharging the US government by $ 1.27 billion for EpiPens.

Noting that Mylan had sought legislation to increase the number of patients who receive prescriptions for EpiPens, Rep. Mick Mulvaney, R-S.C.

On Wednesday, regulators said the company had most likely overcharged Medicaid by $ 1.27 billion for EpiPens.

Online forums for parents struggling to cover the cost for EpiPens often feature at least one user advising other parents to turn to Canada.

Not exact matches

The U.S. Food and Drug Administration (FDA) has given Pfizer's (pfe) Meridian Medical Technologies unit a warning over multiple violations at the Brentwood, Mo. manufacturing plant where it makes EpiPen products for Mylan (myl).

The Food and Drug Administration (FDA) under Commissioner Scott Gottlieb is continuing its quest to ramp up generic drug approvals, this time for complex generics that could compete with products such as Mylan's EpiPen.

Meridian had to issue a recall of the EpiPen and EpiPen Jr. auto - injectors at the end of March as some of the devices, which are used for treating allergic reactions, had a defective part that potentially stopped them from working — an event that could be life - threatening.

As lawmakers and the public scrutinize dramatic price increases for other old drugs — most recently with the Mylan - owned EpiPen, which saw its cost go up by 500 % in the past nine years — the next flash point may be insulin, a drug both ubiquitous and complicated.

Congress seems to think that a trove of documents including anything prepared for the company's board having to do with the EpiPen, Mylan's tax rate, profits connected to the EpiPen, manufacturer contracts related to the EpiPen, anything related to EpiPen pricing in the Netherlands, and anything having to do with a generic EpiPen could help answer that question.

Mylan came under fire in August when it raised the price of the EpiPen, a lifesaving allergy drug, to $ 608 for a two - pack.

«A list of Mylan's profits and expenses relating directly to the sale of EpiPens for each year from 2007 through 2015, including, but not limited to:»

The company previously said it was relying on guidance from CMS about how it classifies EpiPen for the rebate program.

For more on Bresch, read Fortune's 2015 feature, «Why Wall Street Loves to Hate Mylan's CEO» and «Why the CEO Behind the EpiPen Controversy Remains One of Fortune's Most Powerful Women.»

But Slavitt's letter noted that EpiPen, since the fourth quarter of 1997, has been incorrectly reported by its sellers as a generic drug for the rebate program.

For the past five years, Medicaid has spent nearly $ 800 million on EpiPens.

In Canada, a single EpiPen can be bought for $ 100, while the UK National Health Service price for a single dose is closer to $ 38.

Besides, if Mylan were to actually reduce the price of EpiPen, it would have ramifications other than just lowering what individuals pay for the drug.

Her company is best known for jacking up the price of life - saving EpiPen anti-allergy medication, but it also manufactures naloxone, a drug meant to treat opioid over-doses.

Windgap Medical, a Boston - based firm which is trying to release an alternative epinephrine auto - injector with what it says is a superior shelf life to the EpiPen by 2018, for instance.

That means patients who were paying EpiPen's full $ 608 list price (for a package of two) can now get the epinephrine injection device, which is used to treat a potentially fatal allergic reaction known as anaphylaxis, for about half as much.

According to filings, Coury made roughly $ 98 million in 2016, the same year in which the company faced criticism for the price of the EpiPen and the stock fell by almost 30 %, according to company filings.

That could have a domino effect on the other middlemen between Mylan and the patient, such as drug distributors, pharmacy benefit managers, and pharmacies, who might also have to settle for less revenue per EpiPen sale.

Mylan's (myl) EpiPen's price has ballooned about 400 % since 2008, rising from about a $ 100 list price to $ 500 today (many patients are offered a $ 100 coupon for the injecting device, but it's often not enough to cover costs for American families, especially those who have health insurance with high deductibles).

And the risk of losing money also falls less on Mylan than it does on those at the end of the supply chain, with the pharmacy having to dispense EpiPens while accepting less in copay money upfront, then applying for a rebate and waiting to see what trickles back.

The generic pharmaceutical company came into the spotlight in August 2016 for raising the price of the EpiPen to $ 608.61 from $ 93.88 over the past decade.

That's just one reason it's better for Mylan to offer a rebate instead of just slashing the price of EpiPen.

Cosmopolitan reports that keeping an EpiPen on your person is good for emergencies.

A test for the shares looms on Wednesday, when Mylan CEO Heather Bresch testifies before the U.S. House of Representatives Oversight Committee over price increases of EpiPen, an auto - injector of allergy medicine.

For example: Cigna's decision this week to drop coverage of the EpiPen in favor of a cheaper competitor and pharmacy benefits manager Express Scripts» original controversial decision to snub Gilead's hep C cure Sovaldi in favor of a competitor from AbbVie.

Mylan said last month that it would introduce the first generic version of EpiPen for $ 300, half the price of the branded product, as it tries to quell the backlash.

After all, Mylan acquired the EpiPen from another company, and while Bresch insists that significant improvements have been made to the epinephrine - delivering product itself, she also admitted on Thursday that a big part of the price increase rationale was to fund marketing and awareness efforts for the device.